We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Global Autoimmune Disease Therapeutics Market to reach USD 226,194.0 Million by 2035 Amid Rising Prevalence and Advancements in Biologic Therapies | Future Market Insights, Inc.
Future Market Insights Global and Consulting Pvt. Ltd.
9 min read
Future Market Insights Global and Consulting Pvt. Ltd.
The United States remains a leader in managing autoimmune diseases due to its advanced healthcare system and significant investments in research and development. The rising prevalence of conditions such as rheumatoid arthritis and psoriasis has driven demand for effective therapies, particularly biologics like monoclonal antibodies and JAK inhibitors. From 2025 to 2035, the market for autoimmune disease treatments in the U.S. is projected to grow at a CAGR of 1.8%.
NEWARK, Del, March 23, 2025 (GLOBE NEWSWIRE) -- The global autoimmune disease therapeutics market is set to experience significant expansion, with projections indicating an increase from approximately USD 168,614.9 million in 2025 to around USD 226,194.0 million by 2035. This growth, marked by a compound annual growth rate (CAGR) of 3.0%, is driven by multiple factors, including the increasing prevalence of autoimmune disorders, advancements in biologic therapies, and enhanced awareness of early diagnosis and treatment.
Prime Factors Driving And Deterring The Market Growth Of Autoimmune Disease Therapeutics
The global market for autoimmune disease therapeutics is expected to have increased growth in the coming years and there are many factors identified that are likely to bolster the market dynamics in a positive direction.
Besides the propelling factors, a number of challenges are also identified. Let us take an in-depth look at the following drivers and restraints.
DRIVERS:
• Rising Awareness of Autoimmune Diseases: It is anticipated that there is a growing prevalence of autoimmune diseases that are growing the awareness amongst the populace for adopting autoimmune disease therapeutics, boosting the market size.
• Growing Research and Development Activities: It is witnessed that there is a growth in research and development activities to foster the use of ideal therapeutics in the market.
• Emerging Technologies: There are technological advances in screening procedures, wide availability of therapeutics, and a strong presence of pipeline drugs such as baricitinib, certolizumab, secukinumab, and others that are expected to further influence the market growth.
• Increased Automation: Additionally, the analysis of FMI records increased the automation of laboratories that are leading to a diagnosis of several tests that generate fast and error-free results that further fuel the market growth.
RESTRAINTS:
• Inadequate Funding: It is identified that in developing countries there are inadequate funds to flourish adequate adoption and setting up of autoimmune disease therapeutics diagnostics.
• Non-availability of Treatment: It is anticipated that there is a high cost associated with the treatment of autoimmune diseases and their proper treatments are also unavailable in most countries, which is likely to inhibit the market growth.
• Advent of Alternative Technologies: The analysis of FMI unravels the factor that there are a lot of emerging technologies, which are being used as an alternative to therapeutics and are likely to curb the growth of the autoimmune disease therapeutics market.
Opportunities for Market Players
While challenges exist, several opportunities are expected to support market expansion in the coming years:
Emerging Biologic Drug Innovations: Continuous research and development in biologic drugs are introducing novel therapeutic options with improved efficacy and reduced side effects. The rise of next-generation biologics is set to further enhance patient outcomes.
AI-Based Drug Discovery and Development: The integration of artificial intelligence (AI) in drug discovery is accelerating the identification of potential candidates for autoimmune disease treatment. AI-driven platforms enhance efficiency in research, reduce development timelines, and optimize treatment strategies.
Enhanced Patient Access Programs: Governments and healthcare organizations are implementing patient access programs to improve affordability and availability of treatments. These initiatives aim to bridge the gap between high-cost therapies and patient accessibility, ensuring broader treatment coverage.
Government Support: Policies favoring biologic therapies and biotech advancements increase accessibility.
Market Expansion: Growing middle class and pharmaceutical sector improve affordability and access to treatments.
Future Outlook: Innovations in gene and targeted therapies expected to drive long-term market growth.
Forecast: CAGR of 5.1% (2025–2035).
"The autoimmune disease therapeutics market is undergoing a transformative phase, driven by breakthroughs in biologics and precision medicine. The integration of AI in drug discovery and the proliferation of biosimilars are pivotal in enhancing accessibility and affordability. While challenges persist, the market's trajectory remains strong, with technological innovation paving the way for more targeted and efficient treatment solutions," says Sabyasachi Ghosh Associate Vice President at Future Market Insights (FMI) analyst.
Competitive Outlook
The autoimmune disease therapeutics market remains highly competitive, driven by the increasing prevalence of these disorders, advancements in biologic and targeted therapies, and rising investments in immunomodulatory drug development.
To maintain a competitive edge, several companies are focusing on monoclonal antibodies, JAK inhibitors, and innovative biologic therapies. The market is shaped by a dynamic mix of established pharmaceutical giants, biotechnology pioneers, and emerging drug developers, all contributing to the evolving landscape of autoimmune disease treatments.
Explore FMI’s Related Ongoing Coverage on Healthcare Domain:
The global sales of autoimmune disease testing are expected to be approximately USD 4,943.0 million in 2025 and is likely to expand up to approximately USD 8,128.6 million by the end of 2035. The sales are believed to rise with a CAGR of 5.1% during the period of 2025 to 2035. Autoimmune disease testing produced revenue worth approximately USD 4,712.1 million in 2024.
The global lung disease therapeutics market share is likely to garner a market value of USD 83,398.60 million in 2023 and is expected to accumulate a market value of USD 152,369.26 million by registering a CAGR of 6.2% in the forecast period.
Expected to be valued at USD 4.98 billion in 2023, the pleural diseases therapeutics market demand is estimated to register a compounded annual growth rate (CAGR) of 6.5% from 2023 to 2033. According to Future Market Insights, the market is expected to reach USD 9.4 billion by the end of the said forecast period.
The global sandhoff disease therapeutics market growth is expected to garner a market value of USD10 Million in 2023 and is expected to accumulate a market value of USD 17.91 Million by registering a CAGR of 6% in the forecast period 2023 to 2033.
The parkinson’s disease therapeutic market trends is experiencing steady growth, with a projected market size of USD 4.3 billion in 2024. This positive trend is expected to continue, with the market reaching an estimated by USD 6.7 billion 2034. This translates to a CAGR of 5.1% over the next decade.
The CNS treatment and therapy market outlook is set to witness significant expansion in the coming decade, driven by rising neurological disorders, advancements in drug development, and an increasing focus on mental health. According to recent market projections, the overall CNS treatment and therapy market size stood at USD 136.340 million in 2025 and is expected to reach USD 222.090 million by 2035, growing at a CAGR of 5% from 2025 to 2035.
The global dysmenorrhea treatment market overview is forecasted to attain USD 7,167.8 million by 2025, expanding at 7.1% CAGR to reach USD 14,185.1 million by 2035. In 2024, the revenue of this market was around USD 6,727.3 million.
The hypercalcemia treatment market forecast is expected to reach approximately USD 22,640.2 million in 2025 and expand to around USD 52,303.9 million by 2035, reflecting a compound annual growth rate (CAGR) of 8.7% over the forecast period.
The blood cancer treatment market analysis is expected to reach approximately USD 7,065.4 million in 2025 and expand to around USD 18,729.4 million by 2035, reflecting a compound annual growth rate (CAGR) of 9.1% over the forecast period.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
